DURECT (DRRX) Competitors $0.75 +0.03 (+3.57%) As of 04/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DRRX vs. CLYM, ZNTL, VOR, CCCC, PLRX, ANIX, SNTI, CRDL, GALT, and CRVOShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Climb Bio (CLYM), Zentalis Pharmaceuticals (ZNTL), Vor Biopharma (VOR), C4 Therapeutics (CCCC), Pliant Therapeutics (PLRX), Anixa Biosciences (ANIX), Senti Biosciences (SNTI), Cardiol Therapeutics (CRDL), Galectin Therapeutics (GALT), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Climb Bio Zentalis Pharmaceuticals Vor Biopharma C4 Therapeutics Pliant Therapeutics Anixa Biosciences Senti Biosciences Cardiol Therapeutics Galectin Therapeutics CervoMed Climb Bio (NASDAQ:CLYM) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations. Which has more volatility and risk, CLYM or DRRX? Climb Bio has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Which has stronger earnings & valuation, CLYM or DRRX? DURECT has higher revenue and earnings than Climb Bio. DURECT is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$35.12M-$2.13-0.59DURECT$2.03M11.40-$27.62M-$0.27-2.76 Does the MarketBeat Community prefer CLYM or DRRX? DURECT received 314 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 61.48% of users gave DURECT an outperform vote. CompanyUnderperformOutperformClimb BioOutperform Votes2100.00% Underperform VotesNo VotesDURECTOutperform Votes31661.48% Underperform Votes19838.52% Does the media favor CLYM or DRRX? In the previous week, DURECT had 1 more articles in the media than Climb Bio. MarketBeat recorded 1 mentions for DURECT and 0 mentions for Climb Bio. DURECT's average media sentiment score of 1.00 beat Climb Bio's score of 0.00 indicating that DURECT is being referred to more favorably in the news media. Company Overall Sentiment Climb Bio Neutral DURECT Positive Is CLYM or DRRX more profitable? Climb Bio has a net margin of 0.00% compared to DURECT's net margin of -198.58%. Climb Bio's return on equity of -42.21% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -42.21% -41.39% DURECT -198.58%-300.62%-65.17% Do analysts rate CLYM or DRRX? Climb Bio currently has a consensus price target of $10.00, suggesting a potential upside of 693.65%. Given Climb Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Climb Bio is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50DURECT 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders believe in CLYM or DRRX? 69.8% of Climb Bio shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 3.2% of Climb Bio shares are held by company insiders. Comparatively, 3.2% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryClimb Bio beats DURECT on 10 of the 17 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.15M$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-1.226.8921.8017.78Price / Sales11.40231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book1.495.916.443.97Net Income-$27.62M$142.72M$3.21B$247.65M7 Day Performance-0.44%4.38%2.85%1.80%1 Month Performance-6.79%-12.76%-8.64%-6.98%1 Year Performance-18.05%-9.69%11.38%1.34% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT1.1526 of 5 stars$0.75+3.6%N/A-15.1%$23.15M$2.03M-1.2280Short Interest ↓Positive NewsCLYMClimb Bio2.4454 of 5 stars$1.31+2.3%$10.00+663.4%N/A$88.39MN/A-0.629Gap DownZNTLZentalis Pharmaceuticals2.0329 of 5 stars$1.22-0.8%$8.24+575.8%-89.9%$87.61M$67.43M-0.49160VORVor Biopharma1.7091 of 5 stars$0.69-1.3%$8.86+1,181.8%-62.4%$87.40MN/A-0.42140Gap UpCCCCC4 Therapeutics2.4695 of 5 stars$1.23-0.8%$12.50+916.3%-81.8%$87.32M$35.58M-0.72150News CoveragePLRXPliant Therapeutics4.2003 of 5 stars$1.42+6.0%$13.31+837.5%-88.6%$86.96M$1.58M-0.4390Positive NewsGap UpANIXAnixa Biosciences2.9197 of 5 stars$2.65+2.7%$9.00+239.6%-10.8%$85.32M$210,000.00-6.795Gap UpSNTISenti Biosciences2.8056 of 5 stars$3.28+0.6%$10.00+204.9%+25.2%$85.29M$2.56M-0.214Short Interest ↑CRDLCardiol Therapeutics1.6968 of 5 stars$1.03+7.6%$8.40+715.5%-42.3%$85.09MN/A-2.6420Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageGALTGalectin Therapeutics1.4782 of 5 stars$1.34-0.7%$11.00+720.9%-59.2%$84.66MN/A-1.849Gap DownHigh Trading VolumeCRVOCervoMed3.5861 of 5 stars$9.68+14.0%$27.50+184.1%-60.8%$84.25M$7.14M-4.774Short Interest ↓Gap Up Related Companies and Tools Related Companies CLYM Competitors ZNTL Competitors VOR Competitors CCCC Competitors PLRX Competitors ANIX Competitors SNTI Competitors CRDL Competitors GALT Competitors CRVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRRX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DRRX Stock Free DRRX Stock Alerts